---
title: "Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautious"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294316876.md"
description: "Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit andriginal document: Takeda Pharmaceutical Co. Ltd. [4502] Interim report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T07:03:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294316876.md)
  - [en](https://longbridge.com/en/news/294316876.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294316876.md)
generator: "portal-rs"
---

# Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautious

Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit and EPS.

Original document: Takeda Pharmaceutical Co. Ltd. \[4502\] Interim report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13](https://longbridge.com/en/news/296794493.md)
- [Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42](https://longbridge.com/en/news/296395853.md)
- [Takeda says Japan approves ORZEYFUL to treat narcolepsy type 1 in adults](https://longbridge.com/en/news/296745287.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**